Abstract: Among adult participants, factors associated with preexisting M184 V/I included other resistance, Black race, Hispanic/Latinx ethnicity, lower baseline CD4 cell count, advanced HIV disease, longer duration of antiretroviral therapy, and greater number of prior third agents.
Abstract: At last on-treatment visit, 98% (179/182) with preexisting M184 V/I and 99% (2012/2034) of all B/F/TAF-treated participants had HIV-1 RNA <50 copies/mL, with no treatment-emergent resistance to B/F/TAF.
Abstract: CONCLUSIONS: M184 V/I was detected in 10% of virologically suppressed clinical trial participants at study baseline.
Abstract: Most substitutions were M184 V (n = 161) or M184 V/I mixtures (n = 10).
Abstract: OBJECTIVE: We in
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Discussion: A combination of RAM similar to those found in this case (M184V, K65R, V108I and E138A) has not been reported in PrEP users.
Discussion: Although theoretically possible, it is unlikely that the short-term and limited drug exposure was sufficient to select for both M184V and K65R, with only few M184V mutations, and even more rarely K65R, described in the literature.
Discussion: However, six cases of HIV infection despite PrEP use have been described previously; in two cases both M184V and K65R were identified.
Discussion: Possible explanations for the PrEP failure in our
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
PMID: 35491829
2022
Antimicrobial agents and chemotherapy
Abstract: Isolate hypersusceptibility to ISL required F227C, in contrast to zidovudine, an NRTI, which required M184V.
Abstract: Six isolates bearing NRTI RAMs (M184V and/or K65R) were resistant to lamivudine (3TC) and emtricitabine (FTC) but not to other approved NRTIs.
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Discussion: In the other trial, STAT, dolutegravir plus lamivudine (DOVATO (c)) were administered in STR to 131 patients; this regimen was modified in 8 patients during the first 24 weeks (5 for HBV infection, 1 for M184V mutation in baseline GRT, 1 for adverse effects, and 1 by patient request).
Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
PMID: 35302390
2022
AIDS research and human retroviruses
Abstract: M184V/I, K103N/S and Y181C were the most commonly occurring mutations, seen in 76%, 51% and 36% children.
Abstract: At BL, K103N (5), E138A/G (4) and M184V (3) were the most common mutations.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
PMID: 35301540
2022
The Journal of infectious diseases
Abstract: Nine women in the TDF/FTC arm had nonnucleoside reverse-transcriptase inhibitor resistance; 1 had the nucleoside reverse-transcriptase inhibitor resistance mutation, M184V.
Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Result: M184V (0.23%, 2/865) was the most common nucleoside reverse transcriptase inhibitors (NRTIs) related mutation followed by T69D (0.12%, 1/865) and T69G (0.12%, 1/865).
Result: NGS was more sensitive in detecting low-frequency mutations and a total of 4 mutations were detected by NGS but missed by Sanger sequencing which including M184V (1.31%), K65E (3.72%), E138G (1.21%), and Y188C (1.04%).
High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
Discussion: Interestingly, the M184V variant was not common (<1%, not shown) in this cohort.
High Rate of HIV-1 Drug Resistance in Antiretroviral Therapy-Failure Patients in Liaoning Province, China.
PMID: 35229630
2022
AIDS research and human retroviruses
Abstract: K65R (29.69%), M184V (28.52%) were the most common NRTIs resistance mutations.
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
PMID: 35192922
2022
Journal of clinical epidemiology
Abstract: Patients failing first-line ART including emtricitabine or lamivudine showed high levels of the M184V/I mutation after two years: 75.7% (95% Credibility Interval [CrI] 61.9%-88.9%) if combined with tenofovir, and 72.1% (95% CrI 56.8%-85.9%) with zidovudine.
HIV mutation literature information.
PMID: 
2022
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT